ФАКТОРЫ ПАТОГЕНЕЗА ГЕСТАЦИОННОИ ГИПЕРТЕНЗИИ
https://doi.org/10.15829/1560-4071-2015-4-118-122
Аннотация
В обзоре литературы представлены мнения учёных и результаты исследований относительно молекулярных механизмов патогенеза гестационной гипер-тензии и влияния социальных, психосоматических и анамнестических факторов на этапы формирования патологии.
Об авторах
Н. А. Конышко
ГБОУ ВПО Смоленский государственный медицинский университет Минздрава России, Смоленск
Россия
доцент кафедры факультетской терапии
Россия
доцент кафедры факультетской терапии
Т. Е. Морозова
ГБОУ ВПО Первый МГМУ им. И. М. Сеченова Минздрава России, Институт профессионального образования, Москва, Россия
Россия
профессор, заведующая кафедрой клинической фармакологии и фармакотерапии
Россия
профессор, заведующая кафедрой клинической фармакологии и фармакотерапии
Список литературы
1. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens, 2007. 25:1105-87.
2. Leeman M. Arterial hypertension in pregnancy. Rev. Med. Brux, 2008; 29 (4): 340-5.
3. Jauniaux E, Hempstock J, Greenwold N, et al. Trophoblastic oxidative stress in relation to temporal and regional differences in maternal. Am. J. Pathol.2003; 162:115-25.
4. Madazli R.,Yuksel M.A. Comparison of clinical and perinatal outcomes in early- and late-onset preeclampsia. Arch. Gynecol. Obstet, 2014; 290(1): 53-7.
5. Delmis J. Hypertension in pregnancy. Lijec. Vjesn2006; 128(11-12): 357-68.
6. Ajne G., Ahlborg G., Wolff K. Contribution of endogenous endothelin-1 to basal vascular tone during normal pregnancy and preeclampsia. Am. J. Obstet. Gynecol, 2005; 193(1): 234-40.
7. George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. Am. J. Hypertens, 2011; 24(9): 964-9.
8. Bellamy L, Casas JP, Hingorami AD. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ, 2007; 335: 974-82.
9. Leeman M. Arterial hypertension in pregnancy. Rev. Med. Brux; 2008: 29(4): 340-5.
10. Kaaja R, Delmis J. Predictors and risk factors of pre-eclampsia. Minerva Ginecol, 2008: 60(5): 421-9.
11. Stepan H, Faber R,Wessel N. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J. Clin. Endocrinol. Metab, 2006; 91: 2424-7.
12. Gadonski G, LaMarca BB, Sullivan E. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension, 2006; 48: 711 -6.
13. LaMarca BB, Cockrell K. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension, 2005; 46: 82-6.
14. Stepan H, Geipel A, Schwarz F Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am. J. Obstet. Gynecol, 2008; 198(2): 175-6.
15. Akolekar R, Etchegaray A, Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Fetal. Diagn. Ther, 2009; 25(3): 320-7.
16. De Vivo A, Baviera G. Endoglin, PIGF and sFlt-1 as markers for predicting pre-eclampsia. Ada Obstet Gynecol Scand, 2008; 87(8): 837-42.
17. Gilbert JS, Ryan MJ. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J. Physiol. Heart. Circ. Physiol, 2008; 294(2): 541-50.
18. Shah TJ, Leik CE, Walsh SW. Neutrophil infiltration and systemic vascular inflammation in obese women. Reprod. Sci, 2010; 17(2): 116-24.
19. Suzuki X Yamamoto T. Evaluation levels of cytokines in amniotic fluid of women with intrauterine infection in the early second trimester. Fetal. Diagn. Ther, 2006; 21(1): 45-50.
20. Stepan H, Faber R. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J. Clin. Endocrinol. Metab. 2006; 91: 2424-7.
21. Zhou CC, Ahmad S, Mil Angiotensin II induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ. Res. 2007; 100: 88-95.
22. Llinas M, Wallukat G. Agonistic autoantibodies to the AT1 receptor in a rat model of preeclampsia induced by chronic reductions in uterine perfusion pressure (RUPP). Hypertension 2005; 46: 884.
23. SibaiB, DekkerG. Pre-eclampsia. Lancet 2005; 365: 785-99.
24. Timmermans S, Jaddoe VW, Folic acid is positively associated with uteroplacental vascular resistance: The Generation R Study. Nutr. Metab. Cardiovasc. Dis 2009; 9: 1311-20.
25. Yajnik CS. Transmission of obesity-adiposity and related disorders from the mother to the baby. Ann. Nutr. Metab. 2014; 64: 8-17.
26. Food and Drug Administration (USA) information on SafeFetus.com. http://www.safefetus. com/index.htm, 01.02.2014.
Рецензия
Для цитирования:
Конышко Н.А., Морозова Т.Е. ФАКТОРЫ ПАТОГЕНЕЗА ГЕСТАЦИОННОИ ГИПЕРТЕНЗИИ. Российский кардиологический журнал. 2015;(4):118-122. https://doi.org/10.15829/1560-4071-2015-4-118-122
For citation:
Konyshko N.A., Morosova T.E. FACTORS OF GESTATION HYPERTENSION PATHOGENESIS. Russian Journal of Cardiology. 2015;(4):118-122. (In Russ.) https://doi.org/10.15829/1560-4071-2015-4-118-122
Просмотров:
670
Послать статью по эл. почте 